Wealth Enhancement Advisory Services
CGON icon

Wealth Enhancement Advisory Services’s CG Oncology CGON Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$502K Buy
6,676
+303
+5% +$19.8K ﹤0.01% 2682
2026
Q1 		$430K Buy
6,373
+866
+16% +$49.1K ﹤0.01% 2455
2025
Q4 		$222K Buy
5,507
+22
+0.4% +$910 ﹤0.01% 3186
2025
Q3 		$208K Buy
+5,485
New +$159K ﹤0.01% 3105

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wealth Enhancement Advisory Services's CGON Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its CG Oncology (CGON) stake by 4.8% in Q2 2026, buying an estimated $19.8K and bringing the position to 6,676 shares worth $502K. The position accounts for ﹤0.01% of the portfolio, ranked #2682.

Wealth Enhancement Advisory Services first reported a position in CGON in Q3 2025 and has held it in 4 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Wealth Enhancement Advisory Services held 6,676 shares of CG Oncology worth $502K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 303 CG Oncology shares in Q2 2026, an estimated $19.8K.
  • CG Oncology made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2682 holding.
  • Wealth Enhancement Advisory Services first reported a position in CG Oncology in Q3 2025 and has held it in 4 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.